Financing ·
Prices $3.39M of convertible notes and settles Lind litigation for $625,000
ABVCAbvc Biopharma, Inc.
ABVC BioPharma closed a private placement of senior convertible promissory notes with an aggregate principal amount of $4,106,060 for gross proceeds of $3,387,500. The notes carry a 17.5% original issue discount and mature on June 30, 2027. Concurrently, the company entered into a settlement agreement with Lind Global Fund II to resolve litigation, paying $625,000 to satisfy outstanding claims and cancel related debt. Shareholders also approved the 2026 Equity Incentive Plan and an issuance of shares for land acquisition in Taiwan. ABVC BioPharma is a clinical-stage biopharmaceutical company developing drugs for central nervous system disorders and oncology.